Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Pharmacogenet Genomics. 2013 Sep;23(9):470–478. doi: 10.1097/FPC.0b013e328363c137

Table 2.

Participant characteristics of angioedema cases and ACE inhibitor-exposed controls in ONTARGETACE, angiotensin-converting enzyme; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial.

Cases (19) [n (%)] Controls (57) [n (%)]
Sex (male : female) 12 (63.2) : 7 (36.8) 36 (63.2) : 21 (36.8)
Age (years) 64.5±7.5 64.5±7.3
Race (African : European : other) 1 (5.3) : 16 (84.2) : 2 (10.5) 3 (5.3) : 48 (84.2) : 6 (10.5)
Treatment (ramipril : telmisartan : combination) 15 (78.9) : 0 : 4 (21.1) 20 (35.1) : 18 (31.6) : 19 (33.3)